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Cerebrospinal Fluid spermidine, 
Glutamine and putrescine predict 
postoperative Delirium Following 
elective orthopaedic surgery
Xiaobei pan1, emma L. Cunningham  2, Anthony p. passmore2, Bernadette McGuinness2, 
Daniel F. McAuley3, David Beverland4, seamus o’Brien4, tim Mawhinney5, 
Jonathan M. schott  6, Henrik Zetterberg7,8,9,10 & Brian D. Green1,11
Delirium is a marker of brain vulnerability, associated with increasing age, pre-existing cognitive 
impairment and, recently, cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease. This nested 
case-control study used a targeted quantitative metabolomic methodology to profile the preoperative 
CSF of patients (n = 54) who developed delirium following arthroplasty (n = 28) and those who did 
not (n = 26). The aim was to identify novel preoperative markers of delirium, and to assess potential 
correlations with clinical data. Participants without a diagnosis of dementia (≥65 years) undergoing 
elective primary hip or knee arthroplasty were postoperatively assessed for delirium once-daily for 
three days. Groups were compared using multivariate, univariate and receiving operator characteristic 
(ROC) methods. Multivariate modelling using Orthogonal Partial Least Squares-Discriminant Analysis 
(OPLS-DA) of metabolomic data readily distinguished between delirium and control groups (R2 ≤ 0.56; 
Q2 ≤ 0.10). Three metabolites (spermidine, putrescine and glutamine) significantly differed between 
groups (P < 0.05; FDR < 0.07), and performed well as CSF biomarkers (ROC > 0.75). The biomarker 
performance of the two polyamines (spermidine/putrescine) was enhanced by ratio with CSF Aβ42 
(ROC > 0.8), and spermidine significantly correlated with Aβ42 (pearson r = −0.32; P = 0.018). These 
findings suggest that spermidine and putrescine levels could be useful markers of postoperative 
delirium risk, particularly when combined with Aβ42, and this requires further investigation.
Delirium is an acute confusional state1 which is unpleasant for patients, their families and healthcare staff2. It is 
associated with significant negative outcomes including dementia, institutionalisation and death3. Postoperative 
delirium is common, developing after 17% of planned joint replacement surgeries4. Delirium is a marker of brain 
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vulnerability, associated with increasing age, pre-existing cognitive impairment5,6 and, recently, cerebrospinal 
fluid (CSF) biomarkers of Alzheimer’s disease (AD)7. Whilst the pathophysiological basis for delirium remains 
unclear, it is thought to represent, at least partly, an aberrant stress response8.
Metabolomics is a relatively new technique which can comprehensively and simultaneously detect distur-
bances in the metabolome in a high-throughput manner9,10. As metabolomics directly measures chemical pro-
cesses involving metabolites, it holds huge potential as a discovery platform for identifying novel diagnostic 
biomarkers and elucidating disease pathogenesis. The metabolomic analysis of brain tissue, CSF and plasma has 
advanced our understanding of the processes leading ultimately to dementia11–13.
Two previous studies have investigated the alteration of metabolites to samples from delirium and no delirium 
groups in a fracture population, one studying plasma samples14 and one utilising both blood and CSF15. Guo et al. 
reported multiple preoperative metabolic pathways disturbance in postoperative delirium groups including defi-
ciency of ω3 and ω6 fatty acids, energy metabolism and oxidative stress with interactions between hypoxia and 
mitochondrial dysfunction, as well as disorders in the Glu–Gln cycle14. Watne et al. applied high performance 
liquid chromatography (HPLC) to measure amino acids and monoamine metabolites in CSF and serum and 
found increased levels of methionine, phenylalanine, tryptophan and tyrosine in fracture patients who went on to 
develop postoperative delirium15. Fracture patients are older and sicker at baseline16,17, have by definition already 
experienced trauma and often have preoperative delirium18. Elective orthopaedic populations, by contrast, permit 
comprehensive preoperative and premorbid cognitive assessment and CSF sampling at a clinically homogenous 
point, whilst still seeing a significant incidence of delirium.
The aim of the current nested case-control study was to employ a targeted quantitative metabolomic meth-
odology to profile the CSF metabolome of patients who developed delirium following arthroplasty compared to 
those who did not. The aim was to test the hypothesis that CSF metabolomic profiles differ in those who devel-
oped delirium following arthroplasty from those who did not.
Methods
study population. Participants aged 65 years or older admitted for primary elective hip or knee arthroplasty 
to a single surgical centre and planned to undergo spinal anaesthesia with intrathecal diamorphine analgesia were 
eligible for inclusion. Exclusion criteria included a pre-existing diagnosis of dementia or other neurodegenerative 
condition. Between March 2012 and October 2014, 315 participants completed the study. Average age was 74.4 
years and 57% were female. American Society of Anesthesiologists (ASA) physical status classification was avail-
able for 53 of the 54 participants. Of these, one participant was ASA 1, 43 were ASA 2 and nine were ASA 3. The 
incidence of postoperative delirium in our cohort was 44/315 (14%).
study Methods. Study methods are summarised in Fig. 1. Written informed consent was obtained from all 
participants and the study was approved by, and performed in accordance with, local ethical committee proce-
dures (Office for Research Ethics Committees Northern Ireland; REC reference: 10/NIR01/5; protocol number: 
09069PP-OPMS). Demographic data and potential confounding variables including age, gender, type of sur-
gery, Charlson Comorbidity Index (CCI)19, level of education, estimated IQ20 and the Vertical Visual Analogue 
Pain Scores21 were collected preoperatively and included in analyses. Baseline neuropsychological tests included 
Colour Trails 222 and Mini Mental State Examination23.
Postoperatively participants were assessed for delirium once daily by a single researcher for the first three 
days. Delirium was diagnosed using the Confusion Assessment Method (CAM)24 and daily assessments were 
supplemented by post-discharge reviews of the nursing and medical notes. In all cases where there were reports 
of possible delirium but CAM criteria were not fulfilled, cases were then discussed between ELC and APP and 
a consensus reached as to whether they reflected delirium according to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) IV criteria25.
Anaesthe c 
and surgery
Par cipant 
admi ed
Preopera ve 
assessment CSF sampled 
Daily 
delirium 
assessments
Par cipant
discharged
Targeted qua ta ve metabolomic profiling of CSF 
and sta s cal analysis
Figure 1. Flowchart summarising study design and methods. Matched samples n = 28 with delirium and n = 26 
without delirium were used for this study.
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DNA collection, processing and analysis. Venous blood was sampled preoperatively into PAXgene 
Blood DNA tubes (PreAnalytiX; Qiagen/BD, Catalogue No. 761125). All samples were transported to the labora-
tory within 12 hours of collection.
DNA samples were processed according to the manufacturer’s instructions (TaqMan Single Nucleotide 
Polymorphism Genotyping Assay; Life Technologies; Catalogue No. 4351379).
DNA was analysed using the TaqMan Single Nucleotide Polymorphism Genotyping Assay (Life Technologies; 
Catalogue No. 4351379) as per the manufacturer’s instructions. APOE status was inferred from the genotype at 
each of the two alleles, rs7412 and rs42935826.
CsF collection and processing. Spinal anaesthesia was carried out, fasting, in the sitting or lateral posi-
tions using 25 gauge (diameter 0.53 mm; length 90 mm) Whitacre type spinal needles with graduated metal intro-
ducers (Vygon). Once CSF was obtained, a 5 ml syringe (BD Plastipak; BD) was attached to the spinal needle and 
up to 5 mls of CSF withdrawn by the anaesthetist. The CSF was immediately transferred to a 30 ml sterile polypro-
pylene universal container (Unisurge) which was placed on wet ice in an insulated container.
All samples were transported to the laboratory within 12 hours of collection. CSF samples were centrifuged at 
4 °C at 3000 rpm/1811 g for 5 minutes with no brake and 500 mcl aliquots of the supernatant pipetted (Sarstedt, 
Germany, Catalogue No. 70.762) into 1.5 ml polypropylene tubes (Sarstedt, Germany, Catalogue No. 72.69.001) 
and stored at −80 °C.
CsF analysis for Aβ42, T-tau and P-tau. CSF samples were transported to the Leonard Wolfson 
Biomarker Laboratory, University College London on dry ice. There Aβ42, T-tau and P-tau were analysed by 
a single, trained, technician, blinded to the clinical data, using the INNOTEST β-amyloid (1–42), hTau Ag and 
Phospho-tau (181 P) ELISA kits respectively (Fujirebio, Ghent, Belgium) run on a FLUOstar Omega BMG 
LABTECH instrument (chemiluminescent plate reader) according to the manufacturer’s protocols. Samples were 
thawed at 21 °C in an air-conditioned lab and vortexed prior to use. CSF biomarker values were determined using 
Omega software (version 5.10 R2) and a 4-parameter curve fit. Intra- and inter-assay CVs, respectively, were 2.0% 
and 3.9% for Aβ42, 3.3% and 8.1% for T-tau and 1.6% and 5.1% for P-tau. Longitudinal stability in the measure-
ments is further monitored in the laboratory by participation in the Alzheimer’s Association Quality Control 
program27.
targeted metabolomics. Quantitative mass spectrometry-based metabolomic profiling was performed 
using the Biocrates AbsoluteIDQ p180 (BIOCRATES, Life Science AG, Innsbruck, Austria). All sample prepara-
tory steps were carried out according to the manufacturer’s instructions28,29 and analysed on a triple-quadrupole 
mass spectrometer (Xevo TQ-MS, Waters Corporation, Milford, USA). The data were recorded in a 96-well for-
mat and seven calibration standards were integrated in the kit. Metabolites (amino acids and biogenic amines) 
were derivatised using phenylisothiocyanate (PITC) in the presence of isotopically labelled internal stand-
ards, separated using a UPLC (I-Class, Waters Corporation, UK) system with a reverse phase column (Waters 
ACQUITY UPLC BEH C18 2.1 × 50 mm, 1.7 μm; UK) and quantified using a triple-quadrupole mass spectrome-
ter (Xevo TQ-MS, Waters Corporation, UK) operating in the multiple reaction monitoring (MRM) mode. All the 
remaining metabolites (acylcarnitines, hexoses, glycerophospholipids, and sphingolipids) were quantified using 
the same mass spectrometer without column separation by the flow injection analysis (FIA) operating in MRM 
mode. Metabolite concentrations were calculated and expressed as micromolar (µM). The mean of the coefficient 
of variation (CV) for the 180 metabolites in repeated quality controls was 0.12, and 85% of the metabolites had a 
CV of <0.15.
statistical analysis. Powering of original study. The observational cohort study was powered to detect a 
difference in the risk of postoperative delirium between the APOE ε4 positive and negative groups based on an 
estimated APOE ε4 carrier rate of 25.5%30 and a rate of delirium in the APOE ε4-positive and APOE ε4-negative 
groups of 28% and 11%, respectively, in an elective non-cardiac surgery population31. It was estimated that 316 
participants would be required to enable detection of significant difference, at the 5% significance level, with 90% 
power.
Selection of cases and controls. Participants, with and without postoperative delirium, with sufficient CSF availa-
ble to facilitate metabolomic analysis were identified. Samples for this study were selected primarily based on CSF 
availability. Availability of CSF was not associated with delirium in this cohort7. Delirium and control groups were 
matched for age and gender. Initially two groups of n = 27 each were identified but when additional medical notes 
became available and were reviewed one participant was reclassified as having had delirium using the methods 
outlined above, leaving n = 28 cases and n = 26 controls.
Included covariates. Preoperative clinical variables previously shown to be associated with delirium in our 
cohort (Cunningham et al. 2017, Cunningham et al. 2018) were included in the analyses. Data for perioperative 
intravenous opioid use was insufficient and this was therefore excluded.
Statistical Analysis of Metabolomic Data. Concentration data for 187 metabolites were appropriately refor-
matted and exported to Simca 15 (Umetrics, Umeå, Sweden) for multivariate analysis. Data were grouped into 
delirium and control prior to analysis by principal component analysis (PCA) identifying any potential outliers, 
followed by partial least squares-discriminant analysis (PLS-DA). The validity of the model was evaluated based 
on the residuals (R2X, R2Y) and the model predictive ability parameter (Q2) determined through the default 
leave-1/7th-out cross validation. The number of components for the PLS-DA model was optimized using y-table 
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permutation testing (n = 500) and an ANOVA based on the cross-validated predictive residuals (CV-ANOVA)32. 
For CV-ANOVA assessment of significance, a p-value less than 0.05 was considered as significant. Variable 
importance in projection (VIP) plots was created to Identify the top metabolites responsible for discriminat-
ing between groups. The normality of data were tested using SPSS (version 24). Student’s t-test for metabolites 
exhibiting a normal distribution or the Wilcoxon Mann-Whitney test for metabolites exhibiting non-normal 
distributions, and false discovery rates (FDR, q-value) were performed to determine if metabolites were statis-
tically different between two groups (p < 0.05, q < 0.07) (Metaboanalyst Version 3.5; (Xia et al., 2015). The FDR 
adjustment of P-values for multiple comparisons within Metaboanalyst applies the Benjamini & Hochberg cor-
rection method33. In order to assess and compare the biomarker performance of metabolites and/or Aβ42 receiver 
operating characteristic (ROC) curves were constructed (GraphPad Prism, version 6.0). This initially examined 
individual concentration data and subsequently assessed metabolite/Aβ42 ratios as a method of enhancing overall 
biomarker performance.
Results
Matching of Groups. The baseline characteristics of the delirium and control groups, matched for age and 
gender, are shown in Table 1.
Multivariate analysis of metabolomics and clinical data. A PLS-DA model using metabolomics 
data only (Fig. 2A) was able to discriminate the delirium from the control subjects. With 2 components, the 
PLS-DA model was able to discriminate the two groups with R2X(cum) = 0.178, R2Y(cum) = 0.707, Q2 = 0.175. 
CV-ANOVA was used to validate the model (p = 0.016). When the same PLS-DA model was then applied to 
the pre-existing variables (as listed in Table 1), the PLS-DA model could only discriminate two groups with 
R2X(cum) = 0.266, R2Y(cum) = 0.473, Q2 = 0.123 (Fig. 2B). The p value for CV-ANOVA was 0.122 for the 
model, representing a statistically non-validated separation between the two groups. In addition, the predic-
tive ability of the same PLS-DA model was significantly improved with the addition of the metabolomics data: 
R2X(cum) = 0.147, R2Y(cum) = 0.779, Q2 = 0.24 (Fig. 2C). The p value for CV-ANOVA was 0.79 × 10−3. The 
PLS-DA loading plots showed the most influential variables that led to the separation between two groups. 
Combining metabolomic and clinical data improved the predictive ability (Q2 values from 0.175 and 0.123 for 
metabolome and pre-existing variables respectively to 0.24 for combination) for discrimination between two 
groups. The model was also validated using a permutation analysis (n = 500, Supplementary Fig. 1), in which the 
lower Q2 intercept indicated the robustness of the model and lower risk of over-fitting. The top 20 discriminatory 
metabolites/pre-existing variables between two groups identified by Variable importance in projection (VIP) 
are shown in Table 2. The top 5 discriminatory variables consisted of 4 metabolites (spermidine, C16:1-OH, 
glutamine and putrescine) as well as CSF Aβ42 concentrations, of which spermidine, C16:1-OH and glutamine 
contributed more for discrimination between two groups than Aβ42 concentration. The top 20 discriminatory 
metabolites only and top 10 pre-existing variables only are shown in Supplementary Tables 1 and 2.
Metabolites significantly altered in delirium group. Table 3 shows the CSF metabolites significantly 
altered in the delirium patients compared with control group using univariate analysis. P values from t-test, FDR 
q values, fold-change and ROC (AUC) were evaluated. Three metabolites (spermidine, glutamine and putrescine) 
were significantly different between the two groups with p values ≤ 0.05 and q values ≤ 0,07. As gender may sig-
nificantly influence some metabolites34,35, spermidine, glutamine and putrescine are presented, in delirium and 
control subjects, grouped by gender in Fig. 3.
Delirium n = 28 Control n = 26 Statistical Test P value
Age, mean (SD) 76.2 (5.7) 75.9 (5.2) t = 0.224 0.82
Gender, female (%) 15/28 14/26 X2 = 0 1.00
Type of Surgery (hip vs knee), hip (%) 9 out of 28 15 out of 26 X2 = 2.604 0.11
Charlson Comorbidity Index 0/1/2/3 (md = 2) 10/12/3/1 16/8/2/0 MWU 0.09
Vertical Visual Analogue Pain Scale pain at rest, mean (SD) 19.7 (24.9) 26.5 (22.7) t = −1.0 0.31
Apolipoprotein, ApoE4 yes (%) (md = 1) 9/27 8/26 X2 = 0 1.00
Years in Education, mean (SD) 11.3 (1.8) 11.4 (2.3) t = −0.3 0.76
Estimated IQ, mean (SD) 106.8 (9.3) 111.7 (7.5) t = −2.1 0.04
Mini Mental State Examination Score, mean (SD) 26.0 (2.8) 27.7 (1.9) t = −2.5 0.02
Time taken to complete Colour Trails 2 (seconds), mean (SD) 205.2(115.1) 146.4 (50.2) t = 2.5 0.02
Qalb, mean (SD) 6.8 (3.2) 5.9 (2.3) t = 1.2 0.26
CSF AB42, mean (SD) 453.0(175.8) 613.9 (190.3) t = −3.2 <0.01
CSF p-tau, mean (SD) 63.9 (23.5) 51.6 (22.0) t = 2.0 0.05
CSF t-tau, mean (SD) 401.0(233.0) 291.3 (181.7) t = 1.9 0.06
p-tau/AB42 ratio 0.17 (0.09) 0.10 (0.08) t = 2.9 <0.01
Table 1. Baseline characteristics for delirium and control groups.
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Correlations between the significantly altered metabolites and Aβ42. We reported in our pre-
vious publication7 that patients who developed delirium had a 26% lower CSF Aβ42 concentration in their 
pre-operative CSF. This was also highlighted in the VIP plots from the PLS-DA model (Table 2). Thus we evalu-
ated the correlation between the Aβ42 and the significantly altered metabolites. Spermidine showed significantly 
negative correlation with Aβ42 with the Pearson r = −0.32 and p = 0.018 (Fig. 4). However, there was no signifi-
cant correlation in glutamine and putrescine with Aβ42 (data not shown). The use of ratios of pairs of metabolites 
is a simple but powerful tool for enhancing biomarker performance36. Each metabolite was subjected to ratioing 
with Aβ42 and this led to improved AUROC values in the case of spermidine/Aβ42 and putrescine/Aβ42, but not 
glutamine/Aβ42 (Fig. 5).
Discussion
We have found that three amine/polyamine compounds – spermidine, glutamine and putrescine – are higher in 
preoperative CSF samples from persons who went on to develop delirium postoperatively than those who did not. 
The addition of metabolomic data to our statistical model increased the ability of the model to identify delirium 
susceptible patients within a population without dementia.
The elevation of polyamine pathway metabolites has previously been reported in brain tissue, plasma and 
CSF from AD patients11,37,38. Furthermore, there is evidence that polyamines are elevated in the brain and plasma 
animal models developing AD pathology12. Interestingly, it has been shown that polyamines can interact with 
and promote the aggregation of Aβ peptides39 forming amyloid plaques, which are a hallmark of AD. Moreover, 
the presence of Aβ peptides appears to increase polyamine metabolism by upregulating ornithine decarboxylase 
activity, which leads to increased polyamine synthesis40,41. These results therefore complement our previous find-
ings that lower CSF Aβ42 (reflecting accumulation of aggregated Aβ in amyloid plaques in the brain42) predicts 
postoperative delirium. Amyloid pathology causes impaired synaptic function and ultimately damages neurons, 
Figure 2. PLS-DA score plots and loadings plots derived from healthy controls and delirium patients with 
corresponding loadings plot. (A and D) are based on metabolomic data, (B and E) are based on pre-existing 
data, and (C and F) are based on combined data.
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resulting in cognitive impairment and finally dementia43; and likely therefore increases vulnerability to the effects 
of stressors, including opiates, pain, and inflammatory changes seen in surgery44, which may result in delirium.
Understanding the biochemical basis for the development of postoperative delirium is a necessary first step 
if we are to intervene to reduce the incidence of this common, unpleasant and potentially dangerous syndrome. 
Identifying the pathways responsible may also enhance our understanding of neurodegeneration which pre-
disposes to delirium. The study of elective orthopaedic populations permits comprehensive preoperative and 
premorbid cognitive assessment in contrast to research undertaken in fracture populations when participants 
are older and sicker at baseline16,17, have by definition already experienced trauma and often have preoperative 
Figure 3. Box and whisker plots showing the three significantly altered metabolites grouped by gender.
Var ID (Primary) M3.VIP[2]
2.44693 * 
M3.VIP[2]cvSE
1 Spermidine 2.1055 1.50024
2 C16:1-OH 2.02904 1.87932
3 Glutamine 1.86714 1.22719
4 Ab1-42 concentration 1.76284 1.07464
5 Putrescine 1.74713 1.29829
6 p-tau/AB42 1.65976 1.16424
7 Serine 1.59627 1.19567
8 Ornithine 1.55303 0.653106
9 Alanine 1.53883 0.798499
10 Threonine 1.52848 1.15706
11 Valine 1.52002 1.14729
12 Methionine 1.47764 0.979219
13 C14:2-OH 1.38247 1.95308
14 MMSE 1.37368 1.69349
15 Colour Trails 2 (seconds) 1.35567 0.818909
16 C18:2 1.34463 1.34492
17 Estimated IQ 1.34086 1.94578
18 p-tau concentration 1.33876 1.04131
19 Lysine 1.28182 1.04599
20 C4:1 1.2796 1.95744
Table 2. Highest Ranking metabolites and pre-existing variables from Variable Importance Projection (VIP) 
based on the PLS-DA model.
Metabolites p value FDR ↑/↓ Fold change ROC
Spermidine 0.00014735 0.022545 ↑ 1.21 0.775
Glutamine 0.00090092 0.045947 ↑ 1.12 0.794
Putrescine 0.0017469 0.06682 ↑ 1.32 0.762
Table 3. List of metabolites significantly altered in the delirium group.
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delirium18. The incidence of delirium is sufficiently high to study this condition4, but low enough to likely indicate 
an underlying vulnerability. Although the findings of this nested case-control study are based on a relatively small 
sample and are not immediately translational, the key strengths include the use of fasting samples (all samples 
were preoperative), the detailed clinical information, and the annotated and quantitative metabolomic data.
Conclusions
This study indicates the benefits of applying metabolomic methodologies to conditions such as delirium to deter-
mine susceptibility risk: our findings suggest that CSF levels of spermidine, putrescine, and their metabolite 
precursor glutamine, could be useful markers of postoperative delirium risk, particularly when combined with 
Aβ42. The development of rapid and inexpensive methods of measuring spermidine and putrescine is needed 
to evaluate their utility in larger prospective patient cohorts, and to study whether CSF amines/polyamines are 
markers of underlying neurodegeneration (i.e. preclinical Alzheimer’s disease), or for delirium per se. Replication 
of these findings, in both delirium and AD cohorts, is now necessary.
Data Availability
The raw metabolomic data will be provided with this manuscript on request. After publication it will be submitted 
to an online data repository such as Metabolights. Readers can obtain further information on correspondence 
with the authors.
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